NEW YORK (Reuters Health) – Results of a Mexican study indicate that 2 months of treatment with the antiinflammatory agent diacerein increases insulin secretion and improves A1C levels…
NEW YORK (Reuters Health) – The excess risk of unexplained sudden death in psychiatric patients may be related to diabetes and dyslipidemia rather than to the antipsychotic drugs…
NEW YORK (Reuters Health) – Growth hormone treatment of adults isn’t associated with an increased risk of developing diabetes, according to a new report. “The strength of the…
NEW YORK (Reuters Health) – Diabetes incidence falls during rosiglitazone treatment but returns to baseline after rosiglitazone withdrawal, according to the preprint version of a study that is…
NEW YORK (Reuters Health) – Patients with type 2 diabetes without retinopathy can be safely screened for sight-threatening vision problems every 3 years instead of every 1 or…
NEW YORK (Reuters Health) – The estimated 10-year risk for coronary heart disease (CHD) among adults with diabetes has declined significantly in the past decade, according to a…
NEW YORK (Reuters Health) – For patients with type 2 diabetes not controlled with metformin and a sulfonylurea, the choice of an additional agent should be based on…
NEW YORK (Reuters Health) – In a phase 2 study of patients with diabetic macular edema (DME), intravitreal injections of the vascular endothelial growth factor inhibitor, VEGF Trap-Eye,…
NEW YORK – Hemoglobin A1c (A1C) levels are not sensitive or specific enough to be used to identify children and adolescents with or at risk for diabetes, according…
NEW YORK (Reuters Health) – An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to…